Aurora Innovation, Inc. (AUR)

Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1	-	-	68	82	-
Revenue Growth (YoY)	-	-	-	-17.07%	-	-
Cost of Revenue	717	676	716	677	697	179
Gross Profit	-716	-676	-716	-609	-615	-179
Selling, General & Admin	120	110	119	129	116	39
Operating Expenses	120	110	119	129	116	39
Operating Income	-836	-786	-835	-738	-731	-218
Interest & Investment Income	62	62	59	15	-	4
Other Non Operating Income (Expenses)	-36	-24	-20	114	-20	-
EBT Excluding Unusual Items	-810	-748	-796	-609	-751	-214
Impairment of Goodwill	-	-	-	-1,114	-	-
Other Unusual Items	-	-	-	-	-9	-
Pretax Income	-810	-748	-796	-1,723	-760	-214
Income Tax Expense	-	-	-	-	-5	-
Net Income	-810	-748	-796	-1,723	-755	-214
Net Income to Common	-810	-748	-796	-1,723	-755	-214
Shares Outstanding (Basic)	1,728	1,618	1,327	1,143	621	271
Shares Outstanding (Diluted)	1,728	1,618	1,327	1,143	621	271
Shares Change (YoY)	14.25%	21.93%	16.10%	84.06%	129.15%	131.25%
EPS (Basic)	-0.47	-0.46	-0.60	-1.51	-1.22	-0.79
EPS (Diluted)	-0.47	-0.46	-0.60	-1.51	-1.22	-0.79
Free Cash Flow	-601	-645	-613	-523	-612	-199
Free Cash Flow Per Share	-0.35	-0.40	-0.46	-0.46	-0.99	-0.73
Operating Margin	-83600.00%	-	-	-1085.29%	-891.46%	-
Profit Margin	-81000.00%	-	-	-2533.82%	-920.73%	-
Free Cash Flow Margin	-60100.00%	-	-	-769.12%	-746.34%	-
EBITDA	-815	-765	-814	-716	-715	-215
D&A For EBITDA	21	21	21	22	16	3
EBIT	-836	-786	-835	-738	-731	-218

Updated Jul 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q